GDOX, A Novel Candidate Proto-Oncogene
- Technology Application
- The novel GDOX gene may be useful as the basis for novel therapeutics, diagnostics, and prognostics for cancer.Treatment of cancers overexpressing GDOXDetection and monitoring of cancers overexpressing GDOXCancer vaccines based on GDOX antigens
- Detailed Technology Description
- Researchers at the University of California have identified a novel tumor-associated gene using representational difference analysis (RDA) and differential immuno-absorption (DIA), coupled with cDNA microarray analysis. The novel gene, which the researchers have called GDOX (glioma-derived oncogene on X), is overexpressed in a variety of gliomas. Transfection of a murine glial cell line and human glioblastoma cells with sense cDNA for GDOX results in a dramatic increase in cell proliferation, while transfection with antisense GDOX cDNA results in significant growth arrest and morphological changes. In addition, anti-GDOX antibody-treated tumor cells from various types of human cancers exhibit a dose-dependant decrease in cellular proliferation. Importantly, GDOX over-expression correlates with shorter survival times in human glioblastoma patients. These results suggest that the novel GDOX gene may be clinically useful for the development of cancer diagnostics, prognostics, and therapeutics.
- Supplementary Information
- Patent Number: US7204982B2
Application Number: US2002188840A
Inventor: Liau, Linda M.
Priority Date: 2 Jul 2002
Priority Number: US7204982B2
Application Date: 2 Jul 2002
Publication Date: 17 Apr 2007
IPC Current: A61K0039395 | C07H002104 | C07K001447 | C07K001630 | G01N0033574 | A61K003900
US Class: 4241301 | 4241551 | 4241851 | 514044A | 5360231 | 5360243 | 514044
Assignee Applicant: The Regents of the University of California
Title: Compositions and methods for treatment and detection of multiple cancers
Usefulness: Compositions and methods for treatment and detection of multiple cancers
Summary: (M1) is useful for inhibiting proliferation of human cancer cells derived from brain, lung, prostate, colon, or breast and comprising glioblastoma, astrocytoma or oligodendroglioma cell. (M2) is useful for treating cancer in subject (claimed). (I) and (IV) are useful as pharmaceutical compositions for treating cancer. (III) is used as a vaccine for cancer.
Novelty: Novel immunogenic GDOX polypeptide useful as therapeutic and diagnostic agent of cancer
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Cancer/Tumor
- Application No.
- 7204982
- Others
-
BACKGROUND
Glioblastoma multiforme is the most common primary neoplasm of the central nervous system and remains among the most deadly of human cancers. It has previously been shown that accumulation of multiple genetic lesions underlies the malignant progression of this cancer. Although some of these genetic abnormalities have been well-documented, recent insight into the extent of gene expression differences underlying malignancy reveals that hundreds of gene transcripts may be expressed at significantly different levels between normal and neoplastic cells. Identification of these genes has direct clinical relevance if combined with the development of innovative rational therapies that specifically target these differentially expressed gene products.
Additional Technologies by these Inventors
Tech ID/UC Case
10205/2000-479-0
Related Cases
2000-479-0
- *Abstract
-
None
- *IP Issue Date
- Apr 17, 2007
- *Principal Investigator
-
Name: Linda Liau
Department:
- Country/Region
- USA
